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2214-0247/Copyright ª 2014, TaiwanAbstract This study aims to investigate whether the protein isolated from bladder cancer in
an Indonesian population can produce the polyclonal antibody for clinical markers of bladder
cancer. The participants in this study are bladder cancer patients and healthy persons who
were approved for midstream portion urine collection. The inclusion criteria included bladder
cancer patients who obtained hematuria examination, urine cytology, and initial therapy with
transurethral resection of the bladder; a healthy volunteer who was approved for midstream
portion urine collection but without hematuria history, bladder stones, and signs or symptoms
of tractus urinarius infection. The procedure consisted of tissue preparation, tissue processing,
isolation of membrane cell protein, monitoring of protein in membrane cell, production of
polyclonal antibodies, and dot blot technique. A protein with 122 kDa molecular weight is pre-
sent in epithelial cells of bladder cancer and the normal bladder. A protein with 69 kDa molec-
ular weight is only present in the epithelial cell bladder of normal individuals. In addition, a
protein with molecular weight of 47 kDa is only present in epithelial cells of bladder cancer.
The minimal ratio of polyclonal antibody with antigen is 1:6400 of the antibody and 1:40 of an-
tigen. Subsequently, this concentration was applied to detect proteins with 47 kDa only in
several cancer tissues. Positive results in bladder cancer, but negative results in prostate can-
cer, rectal cancer, and breast cancer were found. The polyclonal antibody produced fromof Urology, Ulin General Hospital, Medical Faculty, Lambung Mangkurat University, Jalan Ahmad Yani
Kalimantan, Indonesia.
.com (H. Prasetya).
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native biomarker for diagnosis and surveillance of bladder cancer.
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Bladder cancer is a malignancy in the seventh position of
incidence in men and women.1 In a developed country, such
as the United States, this malignancy is in 4th position for
men and 10th position for women, and remains
increasing.2,3 In Indonesia, a 10 year study in Cipto Man-
gunkusumo Hospital on 340 patients, had a 15% increase per
year with an average age of 54 years. The transitional
carcinoma is frequency of histopathologic feature (80.66%)
and 60% of patients usually diagnosed at locally advanced
and advanced stage.4 The delay of patients to seek medical
treatment or difficulty of the medical practitioner to obtain
the diagnosis remains a problem in developing countries.
This local problem increases efforts to provide a simple
diagnostic tool to be available in urban or rural health
facilities.
The pattern of a specific polypeptide using a proteomic
approach is a useful tool for detection of urothelial carci-
noma. This technique was applied to identify a new
biomarker for new diagnostic tools. Proteomic approach
focuses on the difference in the protein pattern in bladder
cancer compared to a healthy bladder. Finally, a proteomic
approach would be available for polyclonal antibody pro-
duction then applied as clinical markers of bladder cancer.
As far we know, there is no study to investigate the protein
pattern of bladder cancer in the Indonesian population.
Therefore, this study aimed to investigate whether the
protein isolated from bladder cancer in the Indonesian
population can produce polyclonal antibodies for clinical
markers of the bladder cancer diagnostic tool. Besides, this
study was also conducted to determine the effectivity of
polyclonal antibody to detect bladder cancer.Materials and methods
Patients
The participants in this study were bladder cancer patients
and healthy persons who agreed to participate in this study
and provide a midstream portion of urine collection. The
inclusion criteria included bladder cancer who performed
hematuria examination, urine cytology, and initial therapy
with transurethral resection of the bladder. A healthy
volunteer was approved for midstream portion urine
collection but without hematuria history, bladder stone,
and signs or symptoms of tractus urinarius infection. This
research has been approved by Research Ethics Committee
Faculty of Medicine University of Brawijaya, Malang,
Indonesia.Tissue preparation
Bladder cancer tissue was obtained by transurethral
resection of the bladder. Bladder epithelial cells were also
obtained from healthy volunteers. All specimens were cold
packed in 0.9% NaCl then delivered to the Biomedical
Laboratory, Faculty of Medicine, University of Brawijaya,
Malang, East Java, Indonesia.
Tissue processing
Five grams of tissue were cut into little pieces then inserted
into 10-mL sterile tubes, 5 mL phosphate buffer saline was
added and then centrifuged at 5000 rpm for 15 minutes at
4C. The supernatant then discharged, the phosphate
buffer saline which contains 1.5mM EDTA and 0.5mM
dithiothreitol, pH 7.4, was added to the sediment. The
suspension was replaced into a homogenizer tube. These
tubes were then homogenized at 1000 rpm for 1 minute.
The suspension was then placed in a falcon tube and sub-
sequently centrifuged at 5000 rpm for 15 minutes at 4C.
The supernatant discharged, then 2 mL phosphate buffer
saline, pH 7.4, was added through the tube wall slowly. The
white layer at the surface of the sediment was then
replaced with a new tube and centrifuged at 1000 rpm for
15 minutes at 4C. The sediment was then suspended with
5 mL phosphate buffer saline 500 rpm for 5 minutes at 4C.
The supernatant was discharged and the sediment was
evaluated using Giemsa staining.
Isolation of membrane cell protein
The isolation of the membrane cell protein was done ac-
cording to the previous method with modification.5 The
sediment of cancer epithelium was added to 2 mL of
phosphate buffer saline which contains 0.05% N-Octyl b
glucopyranoside (NOG) then vortexed for 1 minute. This
solution was centrifuged at 5000 rpm for 15 minutes at 4C.
The supernatant was saved, but the sediment was isolated
for protein twice using a similar procedure. All supernatant
was then analyzed using phosphate buffer saline pH 7.4 for
2 nights.
Monitoring of protein in the membrane cell
Monitoring of the protein in the membrane cell was done
according to the protocol from prior studies.6 The protein
sample was heated to 100C for 5 minutes in a buffer so-
lution which contained Tris HCl 5mM pH 6.8, 5% mercap-
toethanol, 2.5% w/v sodium dodecyl sulphate, 10% v/v
glycerol with colour tracking bromophenol blue. A 12.5%
Figure 1 Morphology of cells of (A) normal epithelium and
(B) bladder cancer.
Figure 2 Profile of isolated proteins from normal bladder
epithelium (lanes 1e3) and bladder cancer (lanes 4e7). Protein
of 122 kDa molecular weight is present in the epithelial cells
of bladder cancer and normal bladder. Protein of 69 kDa
molecular weight is only present in the epithelial bladder of
normal individuals. In addition, protein of 47 kDa molecular
weight is only present in the epithelial cell of bladder cancer.
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brilliant blue was chosen for colour material.
Observation specific protein
Observation of specific protein was carried out using pro-
tein pattern in Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) results.
Production of polyclonal antibodies
Male mice, 6e8 weeks old, BALB/C strain were obtained
from Integrated Research and Testing Laboratory, Gadjah
Mada University, Yogyakarta, Indonesia. Antigens used were
specific protein subunits from bladder cancer. The antigen
in the syringe was emulsified with Freund’s Complete
Adjuvant (FCA) (Sigma-Aldrich, Singapore, Singapore)
intraperitoneally with a dose of 100 mg in 100 mL phos-
phate buffered saline (PBS) 10. Booster injections were
performed in Weeks 2e4 by using antigen emulsified with
Incomplete Freund’s Adjuvant (IFA) with the same dose.
The serum was taken 1 week after the last booster.7
Serum collection
Blood was collected from the heart. Blood was taken from
five mice, after that it was collected in sterile tubes and
placed in the incubator with temperature of 37C in a tilted
position for 30 minutes. Then it was stored in a refrigerator
with a temperature of 40C for 10 minutes and then
centrifuged at 10,000 rpm for 5 minutes. The clear liquid
zone was separated from blood clots, put in sterile tubes,
and stored at 20C.7
Dot blot
Dot blot is used as a function serological specificity to
detect reactions between antigens and antibodies. Nitro-
cellulose was cut by measuring 7.5  11 cm and inserted
between two pieces of metal blotter apparatus. Then it was
mounted on the dot blot, incubated overnight at a tem-
perature of 40C until completely absorbed into the nitro-
cellulose membrane. Further Tris buffered saline (TBS)
blocking was carried out with blocking buffer (containing
50mM Tris Base, 0.2M NaCl, 5% skim milk, pH 7.4). The next
stage in the membrane, 50 mL of the primary antibodies
specific to 47 kDA (1:100e1:12800 dilution) was spilled,
incubated for 2 hours at room temperature and placed on a
shaker. The solution was removed, and then washed three
times with TBS-0.05% Tween-20, Affymetric, Santa Clara,
CA, USA. The secondary antibody with 1:2500 dilution was
added. Again it was washed three times with TBS 0.05%
Tween-20 and chromogenic substrate (BCIP-NBT) was
added.7,8
Immunohistochemical analysis
Sections obtained from paraffin-embedded tissues were
placed in an antigen retrieval solution (DAKO, Glostrup,
Denmark), followed by peroxide and protein blocking.Sections were incubated with primary antibodies specific to
47 kDA (1:6400) and then stained using a sensitive avi-
dinestreptavidinehorseradish peroxidase kit (BioGenex,
Fremont, CA, USA) according to the manufacturer’s in-
structions. Five fields (200) per bladder cancer, prostate
cancer, rectal cancer, and breast cancer specimens were
examined randomly. Pictures obtained by microscope
camera system were analyzed by Image-Pro Plus 6.0 image
analysis system (Media Cybernetics Corporation, Rockville,
MD, USA), and integrated optical densities (IOD values)
were obtained. The average IOD value of all the photos of
each group represents the IOD value of the group.Results
Fig. 1 shows the difference of morphology between normal
epithelium and bladder cancer.
The profile of SDS-PAGE showed the difference of mo-
lecular weight in bladder cancer compared to healthy tis-
sue as shown in Fig. 2. A protein of 122 kDa molecular
weight is present in the epithelial cells of bladder cancer
and normal bladder. A 69 kDa protein is only present in
Figure 3 Dot blot among the 47 kDa proteins from epithelial cell of bladder cancer. Vertical dots represent series of antibody
concentration (1/100e1/12800). Horizontal dots represent series of antigen concentration (1/10e1/10240). The minimal ratio of
polyclonal antibody with antigen is 1:6400 of the antibody and 1:40 of antigen (arrow).
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47 kDa protein is only present in epithelial cells of bladder
cancer.
In order to detect the sensitivity of polyclonal antibodies
from bladder cancer specific protein, polyclonal antibody
was reacted with antigen in serial concentrations. The
minimal ratio of polyclonal antibody with antigen is 1:6400
of the antibody and 1:40 of antigen. Subsequently this
concentration was applied to detect proteins of 47 kDa only
in several cancer tissues as shown in Fig. 3.
In order to detect the specifity of polyclonal antibody
from bladder cancer specific protein, we tested the anti-
body in several cancer tissues, including prostate cancer,
rectal cancer, and breast cancer. We found positive results
in bladder cancer, but negative results in prostate cancer,
rectal cancer, and breast cancer as seen in Fig. 4.Figure 4 Test result of polyclonal antibody from isolated protein
cancer, and breast cancer. (A) A positive result is found in bladder c
(B) prostate cancer, (C) rectal cancer, and (D) breast cancer.Discussion
Transitional cell carcinoma of the bladder is a common cause
of bladder cancer in the developing world. This type of
bladder cancer has been often present at an advanced stage
so early diagnosis is warranted. Urinary cytology is widely
used for screening for bladder cancer, it is sometimes diffi-
cult to judge cytology specimens, particularly for low-grade
cancers.9,10 Therefore new, noninvasive methods for
bladder cancer detection would open new possibilities in
diagnosis and monitoring,11 as well as in screening of groups
at risk.12e14 An ideal test to monitor bladder cancer should
be objective, noninvasive, easy to administer and interpret,
and have high sensitivity and specificity. Soluble molecular
markers secreted in urine could serve as urinary markers for
bladder cancer detection, depending on their efficiency tofrom bladder cancer in bladder cancer, prostate cancer, rectal
ancer as shown in brown color, but a negative result is found in
120 H. Prasetya et al.provide early detection capabilities and insight into the
appropriate treatment response and tumor recurrence.15
A previous study found several antigens in urothelium
tissue. Fradet et al,16 showed 25 kDa was expressed as
surface glycoprotein of bladder cancer. Perk et al,17 found
17 kDa was lower expressed or negatively expressed in
normal urothelium. In this study we found that a protein
with 122 kDa molecular weight is present in epithelial cells
of bladder cancer and normal bladder. A protein with
69 kDa only presents in epithelial bladder of normal in-
dividuals. In addition, a protein with 47 kDa only presents in
epithelial cells of bladder cancer. This finding indicated
that 47 kDa of protein is the specific protein expressed in
epithelial cell of bladder cancer. Therefore, this protein is
a good candidate for polyclonal antibody production for
clinical markers of the bladder cancer diagnostic tool.
The perfect urinary marker of bladder cancer should
reliably detect all tumors for the well-being of the patients
and at the same time have a very high specificity to mini-
mize false positive results. This is especially true when
considering screening in general, but also when considering
screenings of high risk groups and patients under suspicion
of bladder cancer.18 In order to detect the sensitivity of
polyclonal antibody from a bladder cancer specific protein,
polyclonal antibody was reacted with antigen in serial
concentrations. The minimal ratio of polyclonal antibody
with antigen is 1:6400 of the antibody and 1:40 of antigen.
Subsequently this concentration was used to detect protein
with 47 kDa only in several cancer tissues. Positive results
were found in bladder cancer, but negative results were
found in prostate cancer, rectal cancer, and breast cancer.
This finding indicates that polyclonal antibody produced
from 47 kDa protein subunits is sensitive and specific to
detect bladder cancer.
Conclusion
Polyclonal antibody obtained from 47 kDa protein subunit is
sensitive and specific to detect bladder cancer and become
an alternative biomarker for diagnosis and surveillance of
bladder cancer.
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